405 results on '"Schiffmann, Jonas"'
Search Results
2. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience
3. Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy
4. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer
5. Local Therapy Improves Survival in Metastatic Prostate Cancer
6. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression
7. Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients
8. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study
9. Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy
10. Limitations of Elastography Based Prostate Biopsy
11. Transrectal Ultrasound (US), Contrast-enhanced US, Real-time Elastography, HistoScanning, Magnetic Resonance Imaging (MRI), and MRI-US Fusion Biopsy in the Diagnosis of Prostate Cancer
12. Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study
13. Shear Wave Elastography for Localization of Prostate Cancer Lesions and Assessment of Elasticity Thresholds: Implications for Targeted Biopsies and Active Surveillance Protocols
14. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy: Informing the debate
15. A proposal of a new nomogram for predicting upstaging in contemporary D’Amico low-risk prostate cancer patients
16. Histoscanning Has Low Sensitivity and Specificity for Seminal Vesicle Invasion
17. Replication Asutay & Västfjäll (2017)
18. Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy
19. True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts
20. Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case–control study
21. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification
22. Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer
23. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy
24. Real-Time Elastography for the Detection of Prostate Cancer
25. Trends in Surgical Management of T1 Renal Cell Carcinoma
26. Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria
27. Identification of Pathologically Favorable Disease in Intermediate-Risk Prostate Cancer Patients: Implications for Active Surveillance Candidates Selection
28. Oncological outcome after radical prostatectomy: Marital status does not make a difference
29. MP83-18 LYMPHATIC VESSEL INVASION PREDICTS BIOCHEMICAL RECURRENCE IN ORGAN CONFINED PROSTATE CANCER. RESULTS OF 2316 EUROPEAN PATIENTS WITHOUT LYMPHNODE DISSECTION
30. MP83-07 SALVAGE RADICAL PROSTATECTOMY FOR RECURRENT PROSTATE CANCER: VERIFICATION OF EAU GUIDELINE CRITERIA
31. MP78-17 IDENTIFYING THE MOST INFORMATIVE PREDICTION-TOOL FOR CANCER SPECIFIC MORTALITY AFTER RADICAL PROSTATECTOMY: COMPARATIVE ANALYSIS OF THREE COMMONLY USED PREOPERATIVE PREDICTION MODELS
32. MP78-09 5-YEARS BIOCHEMICAL RECURRENCE AND OVERALL SURVIVAL RATES AFTER RADICAL PROSTATECTOMY OR HIGH DOSE RADIATION BRACHYTHERAPY WITH ADDITIONAL EXTERNAL BEAM IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER
33. PD49-03 MORTALITY, MORBIDITY AND HEALTHCARE EXPENDITURES AFTER LOCAL TUMOR ABLATION OR PARTIAL NEPHRECTOMY FOR T1A KIDNEY CANCER
34. MP59-18 COMPREHENSIVE ASSESSMENT OF CONTEMPORARY SHORT-, INTERMEDIATE-, AND LONG-TERM ENDPOINTS AFTER EITHER PARTIAL NEPHRECTOMY OR MINIMALLY-INVASIVE RADICAL NEPHRECTOMY
35. PD31-13 PERI-OPERATIVE MORTALITY AND LONG-TERM SURVIVAL AFTER PARTIAL VERSUS RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER
36. PD30-06 MORTALITY RISK FACTORS IN EUROPEAN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. COMPETING RISK ANALYSIS WITH 15-YEARS FOLLOW UP
37. Tumor Volume in Insignificant Prostate Cancer: Increasing Threshold Gains Increasing Risk
38. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer
39. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis
40. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study
41. THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY: MP78-07
42. PATTERNS OF USE OF BONE TARGETED THERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS: A POPULATION BASED STUDY: MP70-09
43. DOES HISTOSCANNING (™) PREDICT POSITIVE RESULTS IN PROSTATE BIOPSY? A RETROSPECTIVE ANALYSIS OF 1,188 SEXTANTS OF THE PROSTATE: MP67-13
44. RISK ASSESSMENT TO PREDICT A POSITIVE BIOPSY USING SHEARWAVE ELASTOGRAPHY.: MP67-09
45. NEOADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH WORSE SHORT-TERM OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: A POPULATION-BASED STUDY: MP61-06
46. BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: IS EVERY PATIENT WITH A PSA OF 0.1NG/ML REALLY RECURRING?: MP58-06
47. INCIDENCE OF INSIGNIFICANT PROSTATE CANCER: A REPORT OF 955 CONSECUTIVE PATIENTS UNDERGOING RADICAL PROSTATECTOMY IN A HIGH VOLUME PROSTATE CANCER CENTER: MP58-09
48. SUBOPTIMAL USE OF NEOADJUVANT OR ADJUVANT CHEMOTHERAPY IN RADICAL CYSTECTOMY PATIENTS: A POPULATION-BASED STUDY: MP60-17
49. 90-DAY MORTALITY REPRESENTS A MORE REALISTIC ENDPOINT THAN 30-DAY MORTALITY AFTER RADICAL CYSTECTOMY: MP60-11
50. SHEARWAVE ELASTOGRAPHY FOR LOCALIZATION OF PROSTATE CANCER LESIONS AND ASSESSMENT OF ELASTICITY THRESHOLDS: IMPLICATIONS FOR TARGETED BIOPSIES AND ACTIVE SURVEILLANCE PROTOCOLS: MP53-15
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.